- Home
- DKI vs PMCB Comparison
DKI vs PMCB Comparison
Compare DKI & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DKI | PMCB |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | DKI | PMCB |
|---|---|---|
| Price | $0.39 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 129.1K | ★ 1.8M |
| Earning Date | 02-11-2026 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 26.19 | N/A |
| Revenue | ★ $10,204,329.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | ★ 100.46 | N/A |
| 52 Week Low | $0.30 | $0.63 |
| 52 Week High | $15.00 | $1.90 |
Technical Indicators
Market Signals| Indicator | DKI | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.79 |
| Support Level | N/A | $0.68 |
| Resistance Level | N/A | $0.78 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 39.25 |
Price Performance
Historical ComparisonAbout DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.